Literature DB >> 28558080

The Relation between Epicardial Fat Thickness and Prognostic Risk Scores.

Sevket Balta1, Cengiz Ozturk1, Turgay Celik1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 28558080      PMCID: PMC5210466          DOI: 10.5935/abc.20160185

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.
Dear Editor, We read the article "The Relationship between GRACE Score and Epicardial Fat Thickness(EFT) in non-STEMI Patients" by Gul et al.[1] The authors concluded that end-systolic and end-diastolic EFTs were found to be increased in the higher GRACE group. Several risk scores including have been evaluated so as to identify high/low risk of mortality or complications in patients with STEMI. These methods have been extensively evaluated for the follow-up of short or long term events.[2] However, some studies showed that the GRACE risk score had low predictive accuracy for mortality. On the other hand, other studies showed that the GRACE risk score had the highest prognostic accuracy for long-term mortality.[2] For this challenge, these risk scores may not give accurate information about high/low risk of mortality or complications in patients with STEMI. So, several risk scores should be evaluated when assessing the relation between any of the risk scores and high/low risk of mortality or complications in patients with STEMI. Furthermore, epicardial tissue as a endocrine organ releases a lot of markers that may be related to oxidative stress, inflammation, endothelial dysfunction and atherosclerosis. Epicardial adiposity can also be associated with cardiovascular mobidity and mortality.[3] Furthermore, EFT is also associated with hyperlipidemia, obesity, diabetes, hypertension, smoking, and carotid atherosclerosis, as well as with cardiovascular risk factors like metabolic syndrome, nonalcoholic fatty liver disease, and chronic kidney disease.4 Moreover, some endocrin tissue dysfunction like thyroid issue is associated with EFT. Furthermore, some inflammatory diseases like psoriasis have higher EFT values and EFT may be a possible marker of endothelial dysfunction and increased cardiovascular risk in patients with psoriasis[5] GRACE risk score may give about mortality or complications in patients with STEMI, but both use the risk scores or inflammatory markers. We believe that these findings will evaluate further studies about EFT and GRACE risk score in STEMI patients.
  5 in total

1.  Epicardial fat thickness should be evaluated with other inflammatory markers and cardiovascular risk factors.

Authors:  Sevket Balta; Sait Demirkol; Zekeriya Arslan; Murat Unlu; Ugur Kucuk; Atila Iyisoy
Journal:  Echocardiography       Date:  2013-07       Impact factor: 1.724

2.  Epicardial fat thickness and cardio-ankle vascular index without other inflammatory markers may not provide information to clinicians about the systemic inflammation.

Authors:  Sevket Balta; Sait Demirkol; Ugur Kucuk; Murat Unlu; Mustafa Dinc; Zekeriya Arslan
Journal:  Cardiology       Date:  2013-04-19       Impact factor: 1.869

3.  Epicardial fat thickness in psoriasis patients.

Authors:  Ilknur Balta; Sevket Balta; Cengiz Ozturk; Sait Demirkol; Mustafa Demir
Journal:  Dermatology       Date:  2014-02-08       Impact factor: 5.366

4.  GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction.

Authors:  Simona Littnerova; Petr Kala; Jiri Jarkovsky; Lenka Kubkova; Krystyna Prymusova; Petr Kubena; Martin Tesak; Ondrej Toman; Martin Poloczek; Jindrich Spinar; Ladislav Dusek; Jiri Parenica
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

5.  The Relationship between GRACE Score and Epicardial Fat Thickness in non-STEMI Patients.

Authors:  Ilker Gul; Mustafa Zungur; Ahmet Cagri Aykan; Teyyar Gokdeniz; Ezgi Kalaycioğlu; Turhan Turan; Engin Hatem; Faruk Boyaci
Journal:  Arq Bras Cardiol       Date:  2016-02-16       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.